Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Semax: Evidence Summary
Evidence summary for Semax across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Semax overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Stroke recovery | Tier B | 6 | Approved in Russia for cerebrovascular conditions |
| Cognitive enhancement | Tier C | 8 | Russian clinical trials, limited Western replication |
| Neuroprotection | Tier C | 10 | Consistent preclinical BDNF data |